Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Issues Quarterly Earnings Results

Posted by Teresa Graham on Mar 28th, 2026

Calidi Biotherapeutics (NYSEAMERICAN:CLDI – Get Free Report) released its earnings results on Friday. The company reported $0.45 EPS for the quarter, FiscalAI reports.

Calidi Biotherapeutics Price Performance

CLDI opened at $0.27 on Friday. The company has a 50 day simple moving average of $0.70 and a two-hundred day simple moving average of $1.18. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.11. Calidi Biotherapeutics has a 1-year low of $0.26 and a 1-year high of $19.20.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Warberg Asset Management LLC purchased a new stake in Calidi Biotherapeutics in the 3rd quarter worth $28,000. Geode Capital Management LLC lifted its position in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares in the last quarter. DRW Securities LLC bought a new position in shares of Calidi Biotherapeutics in the fourth quarter worth about $173,000. Finally, Virtu Financial LLC bought a new position in shares of Calidi Biotherapeutics in the fourth quarter worth about $25,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

(Get Free Report)

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.